NVN Liquidation Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

NVN Liquidation non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Carri Geer	Senior VP & CTO	4.9yrs	Nessun dato	Nessun dato
Tomoko Maeda-Chubachi	Chief Medical Officer	2.3yrs	Nessun dato	Nessun dato
Melvin Whitehead	Senior Vice President of Manufacturing Operations	less than a year	Nessun dato	Nessun dato

2.3yrs

Durata media

Gestione esperta: Il team dirigenziale di 6LUA è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Keegan	Independent Director	7.8yrs	US$182.81k	0.15% € 7.8
Steven Skolsky	Independent Director	2.8yrs	US$162.19k	0.13% € 6.6
Diane Thiboutot	Member of Scientific Advisory Board - Acne Advisor	no data	Nessun dato	Nessun dato
Brian Berman	Member of Scientific Advisory Board -Antiviral Advisor	no data	Nessun dato	Nessun dato
W. Geer	Lead Independent Director	8.9yrs	US$202.90k	0.13% € 6.9
Eric Simpson	Member of Scientific Advisory Board - Inflammatory Skin Disease Advisor	no data	Nessun dato	Nessun dato
Machelle Sanders	Independent Director	6.3yrs	US$163.13k	0.090% € 4.6

7.0yrs

Durata media

67.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6LUA sono considerati esperti (durata media dell'incarico 7 anni).

NVN Liquidation Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media